Formycon and Bio Usawa Partner Bio to Provide FYB201/ BioUcenta (Ranibizumab) Across Sub-Saharan Africa

Formycon, Bio Usawa to introduce ophthalmic medicine in Saharan Africa

Bioeq is also the exclusive holder of the global commercialisation rights for the medicine, Formycon’s biosimilar candidate for Lucentis (ranibizumab). This agreement allows Bio Usawa to register and The post Formycon, Bio Usawa to introduce ophthalmic medicine in Sub-Saharan Africa appeared first on Pharmaceutical Business review.

Formycon and Bio Usawa Partner Bio to Provide FYB201/ BioUcenta (Ranibizumab) Across Sub-Saharan Africa

Formycon announced a partnership between Bioeq AG—licensee and exclusive global commercialization rights holder for Formycon’s biosimilar FYB201—and African biotechnology company Bio Usawa Biotechnology. The agreement grants Bio Usawa exclusive rights to register and commercialize FYB201 under the brand name BioUcenta across Sub-Saharan Africa. Financial terms of the deal were not disclosed.  BioUcenta (biosimilar to Lucentis [ranibizumab]) is a…